Pfizer (PFE)

A couple of the stocks on this list pay more than 6% in dividends.

Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad t...

The healthcare stock's elevated valuation bakes in high expectations, leaving little room for error.

Many dividend investors may be overlooking Pfizer's stock, and that could be a costly mistake.

Eli Lilly is dominating the GLP-1 market with nearly 50% revenue growth and a newly approved oral obesity pill. Pfizer is rebuilding its pipeline with obesity drug ambitions and a committed dividend through its transformation.

Vaxcyte stock catapulted Monday after its pneumococcal vaccine proved it's not inferior to shots from Pfizer and Merck.

Put your money to work generating dividend income with these stocks.

Novo Nordisk covers its dividend, and Pfizer doesn't, but investors appear increasingly worried about Novo's future.

The crowd is looking at the next couple of years. It should be looking five years into the future.

There are blazing deals for some of the top healthcare stocks -- companies with proven track records and dividend yields as high as 6%.

These stocks offer juicy yields and attractive risk-reward profiles.

With the 10-year Treasury yielding around 5.3%, Pfizer, Energy Transfer, and Plains All American offer stocks under $30 with dividend yields between 6% and 7%.

Bristol Myers Squibb isn't a growth stock, but it may offer something to bargain hunters and dividend seekers.

VanEck offers lower costs and double the dividend yield, while Invesco delivered stronger 1-year returns with more balanced holdings.

Novo Nordisk boasts a 33% net margin and fortress balance sheet, while Pfizer trades cheaper but faces major patent cliffs through 2030.

Pfizer has been going through a period of transition.

Inflation is running hot, and the Fed is raising interest rates, but consumers aren't likely to pull back on the products these companies sell.

Regeneron Pharmaceuticals (NASDAQ:REGN) and Sanofi said they are expanding their long-running collaboration to develop and commercialize next-generation medicines for type 2 inflammatory diseases, adding four Regeneron-originated antibody programs and establishing a new equal-sharing economic framew

While Pfizer's dividend looks like a trap, its strong balance sheet and low valuation make it safer.

Pfizer and Bristol Myers Squibb pair big dividends with growing drug pipelines, a rare combination for income-focused pharma investors.

Wall Street expects an even bigger rebound for this beaten-down biotech stock.

These high-yielding stocks offer very durable dividends.

Pharmaceutical company share prices may suffer, but probably not by as much as some might fear.

Both companies are years from commercial scale and burning cash to get there. The difference is in how long each can keep going.

AbbVie pivots toward newer immunology drugs while Pfizer leans on acquisitions to offset pandemic decline, but their financial profiles and valuations tell starkly different stories.